<DOC>
	<DOCNO>NCT02977312</DOCNO>
	<brief_summary>This study assess efficacy safety generic imatinib patient chronic myeloid leukemia ( CML ) Jordan . It multicenter , non-interventional , open-label , prospective study combine retrospective data collection file patient diagnosis Ph+ CML , treat Cemivil ( imatinib ) , visit intervention ( ) additional daily practice perform</brief_summary>
	<brief_title>Study Cemivil® ( Imatinib ) Chronic Myeloid Leukemia Patients Jordan</brief_title>
	<detailed_description>Primary objective Measure proportion Philadelphia chromosome positive ( Ph+ ) CML patient CP treat Cemivil achieve optimal response : - Complete hematologic response ( CHR ) 3 month ; - Minor cytogenetic response ( mCyR ) 3 month ( Ph+ ≤65 % ) ; partial cytogenetic response ( PCyR ) 6 month ( Ph+ ≤35 % ) , complete cytogenetic response ( CCyR ) 12 month ( No Ph+ metaphase ) ; - Major molecular response ( MMR ) 12 month Cemivil therapy [ ratio BCR-ABL1 ABL1 ≤0.1 % International Scale ] ; Assess safety tolerability Cemivil one year treatment , base : - Incidence , severity , relationship adverse event ( AEs ) study medication ; - Serious AEs ; - AEs lead permanent treatment discontinuation ; - Clinically relevant change laboratory test ( accord laboratory reference range ) . Number Subjects evaluate : 91 ( N=33 receive generic imatinib first-line therapy `` first-line patient '' . N=58 switch patented imatinib generic imatinib `` switch patient '' )</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Age ≥18 year Newly diagnose patient Ph+ CML CP ; CML patient start Cemivil treatment since registration Jordan confirm CHR Written inform consent Age &lt; 18 year CML accelerate phase CML blast crisis CML mutation ( ) BCRABL gene Contraindications administration study drug accord approve Summary Product Characteristics ( SPC )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>